Trending Stock News

Westwood Management Increased Its Amazon.Com (AMZN) Stake; Vanda Pharmaceuticals (VNDA) Sentiment Is 1.17, Inc. (NASDAQ:AMZN) Logo

Vanda Pharmaceuticals Inc (VNDA) investors sentiment decreased to 1.17 in Q4 2017. It’s down -0.26, from 1.43 in 2017Q3. The ratio turned negative, as 62 investment managers opened new or increased holdings, while 53 cut down and sold their stakes in Vanda Pharmaceuticals Inc. The investment managers in our database reported: 39.77 million shares, up from 38.89 million shares in 2017Q3. Also, the number of investment managers holding Vanda Pharmaceuticals Inc in top ten holdings decreased from 2 to 1 for a decrease of 1. Sold All: 19 Reduced: 34 Increased: 46 New Position: 16.

Westwood Management Corp increased Amazon.Com Inc. (AMZN) stake by 0.79% reported in 2017Q4 SEC filing. Westwood Management Corp acquired 350 shares as Amazon.Com Inc. (AMZN)’s stock rose 28.13%. The Westwood Management Corp holds 44,570 shares with $52.12M value, up from 44,220 last quarter. Amazon.Com Inc. now has $767.51B valuation. The stock decreased 0.35% or $5.52 during the last trading session, reaching $1581.76. About 2.00 million shares traded., Inc. (NASDAQ:AMZN) has risen 76.78% since May 18, 2017 and is uptrending. It has outperformed by 65.23% the S&P500.

Armistice Capital Llc holds 4.06% of its portfolio in Vanda Pharmaceuticals Inc. for 2.68 million shares. Palo Alto Investors Llc owns 4.16 million shares or 2.72% of their US portfolio. Moreover, Great Point Partners Llc has 2.07% invested in the company for 797,531 shares. The California-based Venbio Select Advisor Llc has invested 1.39% in the stock. Birchview Capital Lp, a Vermont-based fund reported 88,000 shares.

Analysts await Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to report earnings on August, 1. They expect $-0.05 EPS, down 66.67% or $0.02 from last year’s $-0.03 per share. After $0.06 actual EPS reported by Vanda Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts -183.33% negative EPS growth.

Ratings analysis reveals 100% of Vanda Pharma’s analysts are positive. Out of 2 Wall Street analysts rating Vanda Pharma, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $21.0 while the high is $24.0. The stock’s average target of $22.50 is 33.14% above today’s ($16.9) share price. VNDA was included in 2 notes of analysts from November 9, 2016. Aegis Capital initiated it with “Buy” rating and $24.0 target in Wednesday, November 9 report. The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) earned “Outperform” rating by Oppenheimer on Wednesday, April 12.

More news for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) were recently published by:, which released: “Vanda Pharmaceuticals’ (VNDA) CEO Mihael Polymeropoulos on Q1 2018 Results – Earnings Call Transcript” on May 03, 2018.‘s article titled: “Investor Expectations to Drive Momentum within Plains Group Holdings, EnteroMedics, Vanda Pharmaceuticals …” and published on May 10, 2018 is yet another important article.

The stock decreased 1.46% or $0.25 during the last trading session, reaching $16.9. About 338,494 shares traded. Vanda Pharmaceuticals Inc. (VNDA) has risen 15.63% since May 18, 2017 and is uptrending. It has outperformed by 4.08% the S&P500.

Since January 1, 0001, it had 0 buys, and 8 selling transactions for $4.89 million activity.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company has market cap of $880.67 million. The companyÂ’s marketed products include HETLIOZ , a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt (iloperidone), a product for the treatment of schizophrenia. It currently has negative earnings. The Company’s clinical development products include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; Trichostatin A, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.

Since December 7, 2017, it had 0 insider purchases, and 15 insider sales for $49.01 million activity. WILKE JEFFREY A sold 250 shares worth $387,475. $2.17 million worth of, Inc. (NASDAQ:AMZN) shares were sold by STONESIFER PATRICIA Q. On Thursday, February 15 the insider Zapolsky David sold $3.24 million. ALBERG TOM A sold $3.35 million worth of stock or 2,285 shares. On Thursday, February 15 the insider Jassy Andrew R sold $2.90M. On Thursday, February 15 Blackburn Jeffrey M sold $18.50M worth of, Inc. (NASDAQ:AMZN) or 12,666 shares. Reynolds Shelley sold $795,502 worth of stock.

More notable recent, Inc. (NASDAQ:AMZN) news were published by: which released: “, Inc. (NASDAQ:AMZN) Technicals Indicate Stock Consolidating” on May 18, 2018, also with their article: “VP of Alexa leaves Amazon” published on May 17, 2018, published: “Pentagon explains single winner for cloud contract” on May 14, 2018. More interesting news about, Inc. (NASDAQ:AMZN) were released by: and their article: “Amazon Offers More Price Cuts at Whole Foods” published on May 16, 2018 as well as‘s news article titled: “Amazon Needs More Whole Foods Stores” with publication date: May 18, 2018.

Among 55 analysts covering (NASDAQ:AMZN), 52 have Buy rating, 0 Sell and 3 Hold. Therefore 95% are positive. had 302 analyst reports since July 21, 2015 according to SRatingsIntel. The company was maintained on Friday, February 3 by UBS. On Friday, October 27 the stock rating was maintained by Needham with “Buy”. Credit Suisse maintained the shares of AMZN in report on Wednesday, January 11 with “Outperform” rating. Credit Suisse maintained the shares of AMZN in report on Friday, April 20 with “Outperform” rating. The company was maintained on Friday, July 28 by Jefferies. JMP Securities maintained the shares of AMZN in report on Friday, February 2 with “Market Outperform” rating. Benchmark maintained the shares of AMZN in report on Friday, January 29 with “Buy” rating. The stock has “Buy” rating by Maxim Group on Thursday, June 23. The rating was maintained by UBS on Friday, October 23 with “Buy”. Maxim Group maintained, Inc. (NASDAQ:AMZN) on Tuesday, June 6 with “Buy” rating., Inc. (NASDAQ:AMZN) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *